Threshold Pharmaceuticals (Threshold) is a US-based biotechnology company. The company operates in the US and the UK.

The company is engaged in the discovery and development of drugs targeting the severe hypoxia in the microenvironment of solid tumors and the bone marrows of patients with some hematological malignancies. Its products include evofosfamide (formerly TH-302), TH-4000 and 18F-HX4.

Threshold's evofosfamide (formerly TH-302) is based on the company's hypoxia targeted therapeutics technology. It selectively targets tumor cells for the treatment of patients living with cancer. Evofosfamide is being evaluated in two phase three clinical trials and multiple earlier-stage clinical trials. The company has a global license and co-development agreement for evofosfamide with Merck KGaA, with an option to co-commercialize in the US.

Threshold also offers TH-CR-406 (for soft tissue sarcoma); MAESTRO (for pancreatic cancer), TH-CR-415 (for non-squamous non-small cell lung cancer) and TH-CR-408 (for multiple Mmyeloma).

The company's tarloxotinib bromide (TH-4000) is a clinical-stage Hypoxia-Activated Prodrug (HAP) that is designed to release an irreversible, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) under hypoxic conditions.

Threshold also provides TH-CR-601 for non-small cell lung cancer, and TH-CR-602 (head and neck squamous cell carcinoma)

Threshold's [18F]-HX4 is an investigational positron emission tomography (PET) imaging agent for hypoxia developed by Siemens Healthcare Molecular Imaging to potentially identify and quantify the degree of hypoxia in tumors in vivo. PET is a non-invasive nuclear medical imaging technique that produces three-dimensional images of certain functional processes in the entire body or selected organs and tissues.

The company's subsidiary includes THLD Enterprises (UK), Limited.

Scope of the Report

-- About the Company - Historical Details, Current Ownership Structure and basic overview of Threshold Pharmaceuticals, Inc. in terms of revenue, net income, and operating income.

-- Financials - Details about Threshold Pharmaceuticals, Inc. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.

-- Company SWOT Analysis - Outlines Threshold Pharmaceuticals, Inc.’s strengths, weaknesses, and opportunities and threats facing the company.

-- Recent Developments - Showcases Threshold Pharmaceuticals, Inc.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

-- Strategic Evaluation - Provides an overview of Threshold Pharmaceuticals, Inc.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

-- What domain does Threshold Pharmaceuticals, Inc. operate and what are key points about it?

-- What is the product / service portfolio of Threshold Pharmaceuticals, Inc.?

-- How has Threshold Pharmaceuticals, Inc. performed financially from the 2013?

-- How does Threshold Pharmaceuticals, Inc. rank among its peers in terms of revenue and market share?

-- What are Threshold Pharmaceuticals, Inc. strengths and weaknesses and what opportunities and threats does it face?

-- What are Threshold Pharmaceuticals, Inc.’s main growth strategies and how successful has the company been at implementing them?

-- What is the in-house technical capability of Threshold Pharmaceuticals, Inc.? Where does it procure / outsource it?

Reasons to buy

-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost

-- 12 hour delivery time fulfilling your urgent requests as per your requirement

-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics